GlassScriptPhysician profile
James A Moss
NPI 1396056784
$2,512.53
in general payments reported to CMS, 2019-2025
14 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $165 · 2021: $12.06 · 2022: $18.76 · 2023: $90.86 · 2024: $189 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $874 · Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $873.93 |
| Food and Beverage | $836.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alon Medical Technology | $1,223.65 | 2019-2025 | |
| Arthrex, INC. | $667.26 | 2023-2025 | Distal Extremities Implants Soft Tissue H&W Mini Tightropes |
| Axogen | $141.69 | 2020-2025 | |
| Zimmer Biomet Holdings, INC. | $130.19 | 2020 | |
| Acumed LLC | $118.61 | 2024 | Inframe Implant, Acumed, Innate Implant |
| Trimed, INC. | $73.75 | 2019 | |
| Ethicon US, LLC | $34.72 | 2025 | Vistaseal |
| Heron Therapeutics, INC. | $34.34 | 2024 | Zynrelef |
| Endo Pharmaceuticals INC. | $21.32 | 2020 | |
| Innovation Technologies INC | $20.11 | 2024 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $18.76 | 2022 | |
| Glaxosmithkline, LLC. | $16.07 | 2024 | Trelegy Ellipta |
| Nuvasive, INC. | $12.06 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.